Completed PHASE4 INTERVENTIONAL 2-arm NCT04294069

Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial (ADAPT)

Azithromycin Pharmacokinetics and Pharmacodynamics in Pregnancy and Preterm Birth Prevention: Optimizing Dosing to Improve Maternal and Neonatal Outcomes

Sponsor: Christiana Care Health Services

Conditions Preterm Premature Rupture of Membrane

Interventions Azithromycin 500 mg Azithromycin Oral Product

Updated 7 times since 2020 Last updated: Jul 24, 2023 Started: Sep 14, 2020 Primary completion: Dec 27, 2020 Completion: Apr 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Preterm Premature Rupture of Membrane, this trial is completed. The trial is conducted by Christiana Care Health Services and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Aug 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Mar 2022 — Aug 2023 [monthly]

Recruiting PHASE4
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Apr 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Christiana Care Health Services
Thomas Jefferson University

Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States